09688 Overview

Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.

Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.

Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.

Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.

Morgan Stanley's Prediction: Morgan Stanley forecasts a 70-80% probability that WUXI BIO's share price will rise in the next 45 days, following a positive profit alert and management guidance indicating accelerated growth in FY2026.

Earnings Forecast Adjustment: The broker has raised its earnings forecasts for WUXI BIO from 2026 to 2030 by 4-10% and increased the target price from $45 to $50, maintaining an Overweight rating.

Recent Stock Performance: WUXI BIO's stock opened 2.71% higher and reached a peak of $44, marking a two-year high, with a trading volume of approximately 24.89 million shares.

Research Services Momentum: The company is experiencing strong momentum in research services, which is expected to enhance profitability through IP-related revenue and recent out-licensing deals with Vertex and ZAI LAB.

UBS China Market Strategy Report: UBS has released a report highlighting Buy-rated Chinese stocks with significant potential for earnings growth by FY26, focusing on Hong Kong-listed and ADR-listed companies.

Highlighted Stocks: The report includes stocks such as INNOCARE, CARSGEN-B, ZAI LAB, AKESO, and CANSINOBIO, along with their recent performance and short selling data.

Short Selling Data: The report provides short selling figures for the listed stocks, indicating varying levels of short interest, with ZAI LAB and AKESO showing higher short selling ratios.

Related Market Insights: Additional context is provided by Soochow Securities, which lists the top 10 Hong Kong stocks with the highest net buys and sells by southbound funds in the previous week.

Revenue Performance: ZAI LAB reported a total revenue of approximately US$116 million for 3Q25, which fell short of expectations by 16% and 22% according to Citi Research and the market, respectively.

Revised Guidance: The company significantly lowered its 2025 revenue guidance from US$560-590 million to at least US$460 million and abandoned its goal of achieving operational expense balance this year.

Market Reaction: Following the revenue miss and guidance cut, Citi Research adjusted its target price for ZAI LAB from US$69 to US$58, maintaining a Buy/High Risk rating.

Short Selling Activity: ZAI LAB experienced short selling of $134.05 million, with a short selling ratio of 19.425%.